La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sécurité And NotWolfgang H. Oertel

List of bibliographic references

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
000034 Stéphane Palfi [France] ; Jean Marc Gurruchaga [France] ; G. Scott Ralph [Royaume-Uni] ; Helene Lepetit [France] ; Sonia Lavisse [France] ; Philip C. Buttery [Royaume-Uni] ; Colin Watts [Royaume-Uni] ; James Miskin [Royaume-Uni] ; Michelle Kelleher [Royaume-Uni] ; Sarah Deeley [Royaume-Uni] ; Hirokazu Iwamuro [France] ; Jean Pascal Lefaucheur [France] ; Claire Thiriez [France] ; Gilles Fenelon [France] ; Cherry Lucas [Royaume-Uni] ; Pierre Brugieres [France] ; Inanna Gabriel [France] ; Kou Abhay [France] ; Xavier Drouot [France] ; Naoki Tani [France] ; Aurelie Kas [France] ; Bijan Ghaleh [France] ; Philippe Le Corvoisier [France] ; Patrice Dolphin [France] ; David P. Breen [Royaume-Uni] ; Sarah Mason [Royaume-Uni] ; Natalie Valle Guzman [Royaume-Uni] ; Nicholas D. Mazarakis [Royaume-Uni] ; Pippa A. Radcliffe [Royaume-Uni] ; Richard Harrop [Royaume-Uni] ; Susan M. Kingsman [Royaume-Uni] ; Olivier Rascol [France] ; Stuart Naylor [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Philippe Hantraye [France] ; Philippe Remy [France] ; Pierre Cesaro [France] ; Kyriacos A. Mitrophanous [Royaume-Uni]Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
000083 Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France]Rotigotine transdermal patch for the treatment of Parkinson's Disease
000104 François Viallet [France] ; Séverine Pitel [France] ; Sylvie Lancrenon [France] ; Olivier Blin [France]Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease
000223 Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Gunther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis]Donepezil in Parkinson's Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study
000238 E. Perrin [France] ; E. Anand [Royaume-Uni] ; Y. Dyachkova [Autriche] ; T. Wagner [Allemagne] ; S. Frediani [Italie] ; A. Ballerini [Italie]A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania
000351 Emmanuelle Bondon-Guitton [France] ; Santiago Perez-Lloret [France] ; Haleh Bagheri [France] ; Christine Brefel [France] ; Olivier Rascol [France] ; Jean-Louis Montastruc [France]Drug-Induced Parkinsonism: A Review of 17 Years' Experience in a Regional Pharmacovigilance Center in France
000368 Santiago Perezlloret [Argentine, France] ; Gabriela Nano [Argentine] ; Andrea Carrosell [Argentine] ; Elkan Gamzu [États-Unis] ; Marcelo Merello [Argentine]A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients
000452 Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne]Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study
000497 Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson's Disease
000554 A. Annic [France] ; D. Devos [France] ; D. Seguy [France] ; K. Dujardin [France] ; A. Destee [France] ; L. Defebvre [France]Intérêts de la stimulation dopaminergique continue par Duodopa® dans la maladie de Parkinson évoluée: efficacité et tolérance
000596 David Devos [France]Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson's Disease
000854 Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France]Safety and tolerability of growth hormone therapy in multiple system atrophy : A double-blind, placebo-controlled study
000855 A. J. Lees [Royaume-Uni] ; V. Ratziu [France] ; E. Tolosa [Espagne] ; W. H. Oertel [Allemagne]Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
000C13 Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France]Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
000E72 B. Cauchemez [France] ; Th. Lavergne [France] ; F. Extramiana [France] ; C. Siliste [France] ; A. Leenhardt [France] ; Ph. Coumel [France]Ablation endocavitaire des arythmies. Nouvelles modalités d'application de la radiofréquence. Nouvelles énergies

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024